Obesity drug leadership: Recent social media chatter centers on Eli Lilly's commanding position in obesity treatments, with investors noting its market dominance alongside peers in the healthcare space.
Portfolio inclusions: Discussions also reference its appearance in top global portfolios updated as recently as mid-May, where it ranks among standout performers in diversified holdings.
Hedge fund activity: Some traders point to institutional moves, including reductions in certain funds' positions, while others express interest in revisiting the stock following positive sector commentary.
Note: This discussion summary was generated from an AI condensation of post data.
Eli Lilly and Company Insider Trading Activity
Eli Lilly and Company insiders have traded $LLY stock on the open market 72 times in the past 6 months. Of those trades, 0 have been purchases and 72 have been sales.
Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:
- ENDOWMENT INC LILLY has made 0 purchases and 72 sales selling 668,823 shares for an estimated $718,369,475.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Eli Lilly and Company Revenue
Eli Lilly and Company had revenues of $19.8B in Q1 2026. This is an increase of 55.55% from the same period in the prior year.
You can track LLY financials on Quiver Quantitative's LLY stock page.
You can access data on LLY stock through the Quiver Quantitative API.
Eli Lilly and Company Congressional Stock Trading
Members of Congress have traded $LLY stock 15 times in the past 6 months. Of those trades, 7 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 04/14, 11/18 and 1 sale worth up to $15,000 on 03/13.
- REPRESENTATIVE LIZZIE FLETCHER sold up to $15,000 on 04/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 2 purchases worth up to $30,000 on 04/02 and 0 sales.
- REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 1 purchase worth up to $15,000 on 02/26 and 3 sales worth up to $45,000 on 02/09, 01/16, 12/10.
- SENATOR ANGUS S. KING JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/29 and 1 sale worth up to $15,000 on 02/13.
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 11/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Eli Lilly and Company Hedge Fund Activity
We have seen 2,106 institutional investors add shares of Eli Lilly and Company stock to their portfolio, and 1,960 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- J. STERN & CO. LLP removed 4,042,726 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $3,692,666,355
- CAPITAL INTERNATIONAL INVESTORS removed 3,752,688 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $3,427,742,746
- JPMORGAN CHASE & CO added 2,729,791 shares (+26.6%) to their portfolio in Q4 2025, for an estimated $2,933,651,791
- CARDANO RISK MANAGEMENT B.V. removed 2,124,209 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $1,940,273,742
- STATE FARM MUTUAL AUTOMOBILE INSURANCE CO removed 1,721,029 shares (-13.8%) from their portfolio in Q1 2026, for an estimated $1,572,005,098
- FIFTH THIRD BANCORP added 1,497,423 shares (+321.3%) to their portfolio in Q1 2026, for an estimated $1,367,761,142
- ASSENAGON ASSET MANAGEMENT S.A. added 1,208,510 shares (+353.7%) to their portfolio in Q1 2026, for an estimated $1,103,865,119
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Eli Lilly and Company Analyst Ratings
Wall Street analysts have issued reports on $LLY in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 01/20/2026
- B of A Securities issued a "Buy" rating on 12/15/2025
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- BMO Capital issued a "Outperform" rating on 12/04/2025
- Morgan Stanley issued a "Overweight" rating on 11/24/2025
- Bernstein issued a "Outperform" rating on 11/24/2025
- Truist Securities issued a "Buy" rating on 11/19/2025
To track analyst ratings and price targets for Eli Lilly and Company, check out Quiver Quantitative's $LLY forecast page.
Eli Lilly and Company Price Targets
Multiple analysts have issued price targets for $LLY recently. We have seen 16 analysts offer price targets for $LLY in the last 6 months, with a median target of $1274.0.
Here are some recent targets:
- Seamus Fernandez from Guggenheim set a target price of $1183.0 on 05/05/2026
- Emily Field from Barclays set a target price of $1400.0 on 05/05/2026
- Alexandria Hammond from Wolfe Research set a target price of $1325.0 on 05/04/2026
- Carter Gould from Cantor Fitzgerald set a target price of $1230.0 on 05/01/2026
- Terence Flynn from Morgan Stanley set a target price of $1327.0 on 04/10/2026
- Jason Gerberry from B of A Securities set a target price of $1294.0 on 04/02/2026
- Rajesh Kumar from HSBC set a target price of $850.0 on 03/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
